Judge suspends Colorado's price cap on prescription drug Enbrel while lawsuit plays out

A federal judge has issued a preliminary injunction blocking Colorado’s attempt to cap the price of Amgen’s arthritis medication, Enbrel, marking a significant legal development for the pharmaceutical industry. The ruling by Judge Daniel Domenico suggests that the state's Prescription Drug Affordability Board (PDAB) likely overstepped its authority by interfering with federal patent laws. This decision stalls the first-ever price cap set by the board and creates a critical precedent as other states look to implement similar drug-pricing regulations.

Judge Daniel Domenico of the U.S. District Court for the District of Colorado ruled that pharmaceutical manufacturer Amgen is likely to succeed in its lawsuit against the state, primarily because the proposed price cap interferes with federal patent law protections. The injunction prevents the Colorado Prescription Drug Affordability Board (PDAB) from enforcing an Upper Payment Limit (UPL) on Enbrel while the legal challenge proceeds. The PDAB, which was established in 2021, had voted to cap the annual cost of the arthritis drug at $31,000, a significant reduction from the $53,000 currently paid by insurance companies.

The legal battle centers on Enbrel, which has seen its wholesale price increase by more than 1,500% since its market introduction in 1998. While the price cap was not scheduled to take effect until January 1, 2027, the court's intervention highlights the friction between state-level cost-containment measures and federal intellectual property rights. Judge Domenico noted that while many Americans struggle to afford medications, the state could pursue alternative methods such as subsidization or price negotiations rather than imposing mandatory caps that conflict with federal statutes.

Stakeholders have expressed starkly different views on the ruling, with Amgen representatives stating they are pleased the court blocked the enforcement of the UPL and remain confident in their legal position. Conversely, Adam Fox of the Colorado Consumer Health Initiative argued that the legal delay keeps affordable drugs out of reach for residents and criticized the court's suggestion of alternative methods as an oversimplification of the pharmaceutical market. The outcome of this case is expected to influence the PDAB's future actions, as the board is currently considering a similar price cap for the drug Cosentyx.